Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress

Journal of Molecular and Cellular Cardiology

Volumn 42, Issue 3, 2007, Pages 549-558

  Andreadou, Ioanna ^a,b   Sigala, Fragiska ^a   Iliodromitis, Efstathios K ^a   Papaefthimiou, Maria ^b   Sigalas, Constantinos ^a   Aligiannis, Nektarios ^b   Savvari, Paraskevi ^c   Gorgoulis, Vassilis ^c   Papalabros, Efstathios ^a   Kremastinos, Dimitrios Th ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Medical School   (Greece)

Author keywords

Doxorubicin; iNOS; Oleuropein; Oxidative stress; Peroxynitrite

Indexed keywords

3 NITROTYROSINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATINE KINASE MB; DOXORUBICIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; OLEUROPEIN; SODIUM CHLORIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CARDIOTOXICITY; CELL VACUOLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; ENZYME INDUCTION; ENZYME RELEASE; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID PEROXIDATION; MALE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ACUTE DISEASE; ANIMALS; DOXORUBICIN; HEART DISEASES; MALE; MALONDIALDEHYDE; NITRATES; NITRIC OXIDE SYNTHASE TYPE II; NITROSATION; OLEACEAE; OXIDATIVE STRESS; PYRANS; RATS; RATS, WISTAR; TYROSINE;

ANIMALIA; OLEACEAE; RATTUS;

EID: 33847691208     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.11.016     Document Type: Article

References (49)

1. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339 (1988) 900-905
2. Young R.C., Ozols R.F., and Myers C.E. The anthracycline antineoplastic drugs. N. Engl. J. Med. 305 (1981) 139-153
3. Booser D.J., and Hortobagyi G.N. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 47 (1994) 223-258
4. Signal P.K., Deally C.M.R., and Weinberg L.E. Subcellular effects of adriamycin in the heart: a concise review. J. Mol. Cell. Cardiol. l9 (1987) 817-828
5. Yen H.C., Oberley T.D., Vichitbandha S., Ho Y.S., and St Clair D.K. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in trangenic mice. J. Clin. Invest. 98 (1996) 1253-1260
6. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999) 727-741
7. Kawasaki N., Lee J.-D., Shimizu H., Ishii Y., and Ueda T. Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats. Int. J. Cardiol. 55 (1996) 217-225
8. Pacher P., Liaudet L., Bai P., Mabley J.G., Kaminski P.M., Virag L., et al. Potent metalloporhyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 18 (2002) 896-904
9. Weinstein D.M., Mihm M.J., and Bauer A. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J. Pharmacol. Exp. Ther. 294 (2000) 396-401
10. Kang Y., Chen Y., and Epstein P. Suppression of doxorubicin cardiotoxicity by over expression of catalase in the heart of transgenic mice. J. Biol. Chem. 271 (1996) 12610-12616
11. Siveski-Iliskovic N., Kaul N., and Singal P. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89 (1994) 2829-2835
12. Vora J., Khaw B., Narula J., and Boroujerdi M. Protective effect of butylated hydroxyanisole on adriamycin-induced cardiotoxicity. J. Pharm. Pharmacol. 48 (1996) 940-944
13. Morishima I., Matsui H., Mukawa H., Hayashi K., Toki Y., Okumura K., et al. Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats. Life Sci. 63 (1998) 511-521
14. Blatt J. ICRF-187 as a cardioprotectant in children treated with anthracyclines. Pediatr. Hematol. Oncol. 14 (1997) 3-6
15. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev. 56 (1999) 317-333
16. Tuck K.L., Freeman M.P., Hayball P.J., Stretch G.L., and Stupans I. The in vivo fate of hydroxytyrosol and tyrosol, antioxidant phenolic constituents of olive oil, after intravenous and oral dosing of labeled compounds to rats. J. Nutr. 131 (2001) 1993-1996
17. Zarzuelo A., Duarte J., Jimenez J., Gonzalez M., and Utrilla M.P. Vasodilator effect of olive leaf. Planta Med. 57 (1991) 417-419
18. Gonzalez M., Zarzuelo A., Gamez M.J., Utrilla M.P., Jimenez J., and Osuna I. Hypoglycemic activity of olive leaf. Planta Med. 58 (1992) 513-515
19. Hamdi H.K., and Castellon R. Oleuropein, a non-toxic olive iridoid, is an anti-tumor agent and cytoskeleton disruptor. Biochem. Biophys. Res. Commun. 334 (2005) 769-778
20. Andreadou I., Iliodromitis E.K., Mikros E., Constantinou M., Agalias A., Magiatis P., et al. The olive constituent oleuropein exhibits anti-ischemic, antioxidative and hypolipidemic effects in anesthetized rabbits. J. Nutr. 136 (2006) 2213-2219
21. Speroni E., Guerra M.C., Minghetti A., Crespi-Perellino N., Pasini P., Piazza F., et al. Oleuropein evaluated in vitro and in vivo as an antioxidant. Phytother. Res. 12 (1998) S98-S100
22. Puel C., Quintin A., Agalias A., Mathey J., Obled C., Mazur A., et al. Olive oil and its main micronutrient (oleuropein) prevent inflammation-induced bone loss in the ovariectomised rat. Br. J. Nutr. 92 (2004) 119-127
23. Tan H.W., Tuck K.L., Stupans I., and Hayball P.J. Simultaneous determination of oleuropein and hydroxytyrosol in rat plasma using liquid chromatography with fluorence detection. J. Chromatogr., B 785 (2003) 187-191
24. Boccio P., DiDeo A., De Curtis A., Celli N., Iacoviello L., and Rotilio D. Liguid chromatography-tandem mass spectrometry analysis of oleuropein and its metabolite hydroxytyrosol in rat plasma and urine after oral administration. J. Chromatogr., B 785 (2003) 47-56
25. Vissers M.N., Zock P.L., Roodenburg A.J.C., Leenen R., and Katan M.B. Olive oil phenols are absorbed in humans. J. Nutr. 132 (2002) 409-417
26. Cole M.P., Chaiswing L., Oberley T.D., Edelmann S.E., Piascik M.T., Lin S.-M., et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc. Res. 69 (2006) 186-197
27. Kotsinas A., Evangelou K., Zacharatos P., Cittas C., and Gorgoulis V.G. Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)- to S-phase cell-cycle regulators. Am. J. Pathol. 161 (2002) 1619-1634
28. Sigala F., Papalampros E., Kotsinas A., Andreadou I., Sigalas P., Kremastinos D., et al. Relationship between iNOS expression and aortic cell proliferation and apoptosis in an elastase-induced model of aorta aneurysm and the effect of 1400W administration. Surgery 137 (2005) 447-456
29. Poussios D., Andreadou I., Papalois A., Rekka E., Gavalakis N., Aroni K., et al. Protective effect of a novel antioxidant non-steroidal anti-inflammatory agent (compound IA) on intestinal viability after acute mesenteric ischemia and reperfusion. Eur. J. Pharmacol. 465 (2003) 275-280
30. Andreadou I., Iliodromitis E.K., Mikros E., Bofilis E., Zoga A., Constantinou M., et al. Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress. Free Radical Biol. Med. 37 (2004) 500-510
31. ATP channels and cyclic-GMP without inhibiting lipid peroxidation. Free Radical Biol. Med. 41 (2006) 1092-1099
32. Campo G.M., Squadrito F., Campo S., Altavilla D., Quartarone C., Ceccarelli S., et al. Beneficial effect of raxofelast, an hydrophilic Vitamin E analogue, in the rat heart after ischemia and reperfusion injury. J. Mol. Cell. Cardiol. 30 (1998) 1493-1503
33. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A., et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186 (1990) 464-478
34. Zhou S., Starkov A., Froberg M.K., Leino R.L., and Wallace K.B. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 61 (2001) 771-777
35. Vasquez-Vivar J., Martasek P., Hogg N., Masters B.S.S., Pritchard K.A., and Kalyanaraman B. Endothelial nitric oxide synthase dependent superoxide generation from adriamycin. Biochemistry 36 (1997) 11293-11297
36. Zimmerman H.J., and Henry J.B. Clinical enzymology. In: Henry J.B. (Ed). Clinical diagnosis and management by laboratory methods (1988), The W.B. Saunders Company, Philadelphia, PA 317
37. Saad S.Y., Najjar T.A.O., and Alashari M. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and time of administration. J. Biochem. Mol. Toxicol. 18 (2004) 78-86
38. Mihm M.J., Yu F., Weinstein D.M., Reiser P.J., and Baner J.A. Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. Br. J. Pharmacol. 135 (2002) 581-588
39. Varin R., Mulder P., Richard V., Tamiom F., Devaux C., Henry J.P., et al. Exercise improves flow-mediated vasodilation of skeletal muscle arteries in rats with chronic heart failure: role of nitric oxide, prostanoids and oxidant stress. Circulation 99 (1999) 2951-2957
40. Haywood G.A., Tsao P.S., Von der Leyen H.E., Mann M.J., Keeling P.J., Trindade P.T., et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 15 (1996) 1087-1094
41. Adams V., Jiang H., Yu J., Mobims-Winkler S., Fiehn E., Linke A., et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol. 33 (1999) 959-965
42. Lind D.S., Kontaridis M.I., Eduards P.D., Josephs M.D., Moldauer L.L., and Copeland E.M. Nitric oxide contributes to adriamycin's antitumor effect. J. Surg. Res. 69 (1997) 283-287
43. Magrinat G., Mason S.N., Shami P.J., and Weinberg J.B. Nitric oxide modulation of human leukemic cell differentiation and gene expression. Blood 80 (1992) 1880-1884
44. Dong Z., Staroselsky A., Qi X., Xie K., and Fidler I.J. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res. 54 (1994) 789-793
45. Garner A.P., Paine M.J., Rodriguez-Crespo I., Chinje E.C., Ortiz De Montellano P., Stratford I.J., et al. Nitric oxide synthases catalyse the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 590 (1999) 929-1041
46. Sayed-Ahmed M.M., Khattab M.M., Gall M.Z., and Osman A.M. Increased plasma endothelin and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol. Toxicol. 89 (2001) 140-144
47. Joshi P., Vig P.J., Veerisetty V., Cameron J.A., Sekhon B.S., and Desaiah D. Increase in brain nitric oxide synthase activity in daunorubicin-treated rats. Pharmacol. Toxicol. 78 (1996) 99-103
48. Park C.S., Park R., and Krishna G. Constitutive expression and structural diversity of inducible isoform of nitric oxide synthase in human tissues. Life Sci. 59 (1996) 219-225
49. Visioli F., Bellosta S., and Galli C. Oleuropein, the bitter principle of olives, enhances nitric oxide production by mouse macrophages. Life Sci. 62 (1998) 541-546